MBrace Therapeutics is a privately held biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for novel oncology targets. Their goal is to enhance the quality of life for cancer patients by leveraging the potential of ADCs, which combine the specificity of antibodies with the potency of chemotherapy drugs. By targeting specific cancer cells, these ADCs aim to deliver the drug directly to the tumor, minimizing damage to healthy cells and reducing side effects. MBrace Therapeutics is dedicated to advancing the field of oncology and providing innovative treatment options for cancer patients.